Microbot Medical receives Israeli regulatory approval for LIBERTY System, first outside U.S.

Microbot Medical Inc.

Israeli Ministry of Health's AMAR Division grants marketing clearance for LIBERTY Endovascular Robotic System in Israel.
First regulatory approval outside the U.S.; enables Free Sale Certificate for submissions in other jurisdictions.
Company targets CE Mark certification by end of 2026 for EU market expansion.
System adopted by multiple U.S. accounts in GA, FL, NY, MA, MI, NC.
Advanced discussions underway to expedite commercialization in Israel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.